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ABSTRACT 25 
 26 
Collagen IV (Col IV) is a major component of expanded glomerular extracellular matrix in diabetic 27 
nephropathy and Smad1 is a key molecule regulating Col IV expression in mesangial cells (MCs). The 28 
present study was conducted to determine if Smad1 pathway and Col IV protein abundance were 29 
regulated by store-operated Ca2+ entry (SOCE). In cultured human MCs, pharmacological inhibition of 30 
SOCE significantly increased the total amount of Smad1 protein. Activation of SOCE blunted high 31 
glucose-increased Smad1 protein content. Treating human MCs with angiotensin II at 1 µM for 15 min, 32 
or high glucose for 3 days, or TGF-β1 at 5 ng/ml for 30 min increased the level of phosphorylated 33 
Smad1. However, the phosphorylation of Smad1 by those stimuli was significantly attenuated by 34 
activation of SOCE. Knocking down Smad1 reduced, but expressing Smad1 increased the amount of 35 
Col IV protein. Furthermore, activation of SOCE significantly attenuated high glucose-induced Col IV 36 
protein production and blockade of SOCE substantially increased the abundance of Col IV. To further 37 
verify those in vitro findings, we downregulated SOCE specifically in MCs in mice using siRNA against 38 
Orai1 (the channel protein mediating SOCE) delivered by the targeted nanoparticle delivery system. 39 
Immunohistochemical examinations showed that expression of both Smad1 and Col IV proteins were 40 
significantly greater in the glomeruli with positively-transfected Orai1 siRNA compared to the glomeruli 41 
from the mice without Orai1 siRNA treatment. Taken together, our results indicate that SOCE 42 
negatively regulates the Smad1 signaling pathway and inhibits Col IV protein production in MCs. 43 
  44 
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ABBREVIATIONS 45 
 46 
2-APB: 2-aminoethyl diphenylborinate 47 
Ang II: angiotensin II 48 
Col IV: collagen IV 49 
ER: endoplasmic reticulum 50 
IDV: integrated density value 51 
MC: mesangial cell 52 
NP: nanoparticle 53 
p-Smad1: phospho-Smad1 54 
R-Smad: receptor-regulated Smad 55 
siSmad1: small interfering RNA against human Smad1 56 
SOCE: store-operated Ca2+ entry 57 
TG: thapsigargin 58 
 59 
 60 
 61 
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INTRODUCTION 65 
SOCE, the Ca2+ entry through store-operated Ca2+ channel driven by depletion of the ER Ca2+ is 66 
critical to the primary Ca2+ signaling pathway in a variety of cell types (35), including glomerular MC 67 
(27). This Ca2+ signal plays an essential role in a wide variety of physiological functions, such as 68 
stimulating exocytosis, regulating gene transcription and protein production, and influencing cell 69 
proliferation and apoptosis (35). Recently, emerging evidence suggests that the function of SOCE is cell 70 
context dependent. For instance, SOCE contributes to cardiac hypertrophy (19), but suppressed cell 71 
growth in mouse embryonic fibroblasts and rat uterine leiomyoma cells (37). This cell-type dependent 72 
function of SOCE also exists in kidney. In the proximal tubular epithelial cells, Mai et al reported that 73 
blockade of Orai1-mediated SOCE inhibited TGF-β1-stimulated fibronectin protein expression (28). On 74 
the contrary, in glomerular MCs we and Mai et al demonstrated that suppression of SOCE increased 75 
fibronectin protein abundance (28; 46). 76 
In our recent in vitro and in vivo studies, we showed that SOCE decreased abundance of MC-derived 77 
Col IV (46), one of major extracellular matrix proteins produced by MCs. Because over production of 78 
extracellular matrix proteins by MCs and deposition of these proteins to mesangium is an important 79 
contributor to mesangial expansion in the early stage of diabetic nephropathy (14; 15), our finding raises 80 
a possibility that SOCE pathway could be a potential therapeutic target for diabetic kidney disease. 81 
However, the mechanism underlying the inhibitory effect of SOCE is not known yet. 82 
It has been firmly established that Smad signaling pathway plays a crucial role in matrix protein 83 
production (23; 24). Smad signaling is initiated with phosphorylation of R-Smad (Smad1, 2, 3, 5, 8) by 84 
type I receptors of TGF-β superfamily. Once phosphorylated, R-Smads form heteromeric complexes 85 
with Smad4, followed by translocation of the complexes into the nucleus to regulate transcription of 86 
target genes. Classically, Smad2/3 stimulates production of fibronectin  and connective tissue growth 87 
factor (12; 23; 24) while Smad1 promotes Col IV production (3). Smad signaling pathway was recently 88 
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reported in MCs (2; 3; 10; 30; 38). Particularly, it has been reported that Smad1 signaling pathway was 89 
tightly associated with the development of diabetic nephropathy (3; 29; 30). However, the mechanism 90 
for regulation and modulation of Smad1 signaling is still unclear. The present study was conducted to 91 
test a hypothesis that SOCE inhibited Smad1 pathway and reduced abundance of Col IV, a product of 92 
the activated Smad1 pathway. 93 
  94 
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MATERIALS AND METHODS 95 
Materials Information on all antibodies for immunofluorescence experiments was described above. 96 
Human recombinant TGFβ1 (240-B-002) was purchased from R&D systems. TG (T-9033), 2-APB (D-97 
9754), lanthanum chloride (449830), and Ang II (A9525) were purchased from Sigma-Aldrich (Sigma, 98 
ST. Louis, MO). Mouse anti-Col IV antibody (M61403M) was purchased from Meridian Life Science, 99 
Inc. (Memphis, TN). Anti-Smad1 mouse monoclonal antibody (sc-81378 at 1:200), anti-desmin goat 100 
polyclonal antibody (sc-7559), anti-synaptopodin goat polyclonal antibody (sc-21537), and anti-α-101 
tubulin primary antibody (sc-5286) were purchased from Santa Cruz (Dallas, TX). Rabbit polyclonal 102 
anti-phospho Smad1 antibody (06-702 at 1:1000) was purchased from EMD Millipore Corp. (Billerica, 103 
MA). Rabbit polyclonal anti-Orai1 antibody (O-8264) was purchased from Sigma (ST. Louis, MO). 104 
Flag-tagged Smad1 expression plasmid was kindly given by Dr. Xia Lin at Baylor College of Medicine 105 
(Houston, TX). 106 
MC culture Human MCs belong to CloneticsTM renal MC system and were purchased from Lonza 107 
(Catalog #:CC2559, Walkersville, MD). MCs in a 75 cm2 flask were cultured in 5.6 mM D-glucose 108 
DMEM medium (Gibco, Carlsbad, CA) supplemented with 25 mM HEPES, 4 mM glutamine, 1.0 mM 109 
sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/ml penicillin, 100 µg/ml streptomycin and 110 
20% fetal bovine serum. When MCs reached ~90% confluence, the cells were split into 60-mm cell 111 
culture plates for various treatments as specified in figure legends. In some experiments, MCs were 112 
treated with high glucose. In those experiments, the concentration of D-glucose was 25 mM and cells 113 
were growth-arrested with 0.5% serum during treatments. Culture media was replaced with fresh media 114 
every 2 days. Only subpassage 4-9 MCs were used in the present study. 115 
Transient transfection of human MCs siSmad1 was purchased from Santa Cruz (Catalog #: 116 
29483). The siSmad1 and scrambled control siRNA (both 50 nM) were transfected into human MCs 117 
using Dharmafect 2 transfection reagent (Thermo Scientific, Rockford, IL) in serum free DMEM media 118 
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following the protocol provided by the manufacturer. Media was changed to 20% fetal bovine serum 119 
DMEM media after 6 h.  Cells were harvested for Western blot 48 h after transfection. Flag-tagged 120 
expression plasmid of Smad1 (Flag-Smad1) and empty vector (pSHAG) were transfected into MCs at 121 
0.5 µg/ml using Lipofectamine and Plus reagent (Invitrogen-BRL, Carlsbad, CA) following the 122 
protocols provided by the manufacturer. Cells were harvested 48 h after transfection for immunoblot 123 
analysis. 124 
Western blot The whole cell lysates or renal cortical extracts were fractionated by 10% SDS-PAGE, transferred 125 
to PVDF membranes, and probed with primary Col IV, Smad1, p-Smad1, Orai1, β-actin, and α-tubulin antibodies. 126 
Bound antibodies were visualized with Super Signal West Femto or Pico Luminol/Enhancer Solution (Thermo 127 
Scientific, Rockford, IL). The specific protein bands were visualized and captured using an AlphaEase FC 128 
Imaging System (Alpha Innotech, San Leandro, CA). The IDV of each band was measured by drawing a 129 
rectangle outlining the band using AlphaEase FC software with auto background subtraction. The expression 130 
levels of target proteins were quantified by normalization of the IDVs of those protein bands to that of actin or 131 
tubulin bands on the same blot. 132 
Animals All procedures were approved by the University of North Texas Health Science Center 133 
Institutional Animal Care and Use Committee. Nine male C57BL/6 mice were purchased from Charles 134 
River Laboratories (Wilmington, MA). All mice used in this study were between 2 and 3 months of age. 135 
The animals were maintained at the animal facility of the University of North Texas Health Science 136 
Center under local and National Institutes of Health guidelines. 137 
In Vivo delivery of NP into the kidney of Mice The targeted NP-delivery system was used to deliver 138 
siRNA against Orai1 to the kidney of mice as previously described (46). The compositions and 139 
formulation of the NP/siRNA complex were described previously (48).  Mice were randomly divided 140 
into control (n=5) and Orai1–knocked down (n=4) groups. Tail vein injection of NPs containing Cy3- 141 
tagged siRNA against mouse Orai1 (NP-Cy3- siOrai1) were given at a dose of 10 mg/kg siRNA in a 142 
volume of ~100 µl to the mice in the Orai1–knocked down group. The sense strand sequence of the NP-143 
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Cy3-siOrai1 is 5’-/5Cy3/GGGUUGCUCAUCGUCUUUAGUGC-3’. The mice in the control group 144 
were only given unconjugated NPs through the same route at the same injection volume. These 145 
intravenous injections were given on day 1 and 3 of the experiment and the mice were euthanized on day 146 
5. Mice were euthanized via intraperitoneal injection of pentobarbital (100 mg/kg body weight). 147 
Kidneys were perfused with PBS to wash out the blood. The left renal artery was then ligated and the 148 
left kidney was removed for extracting renal cortical proteins. The mouse was then perfused with 4% 149 
paraformaldehyde and the right kidney was then removed and fixed in 4% paraformaldehyde. 150 
Paraformaldehyde-fixed kidney was embedded in molten paraffin and then, was sectioned at 4-5 µm in 151 
thickness (Cryostat 2800 Frigocut-E; Leica Instruments) for immunohistochemical examinations. 152 
Isolating renal cortex and extracting cortical proteins The left kidneys of mice were used to extract 153 
renal cortical proteins. Renal cortex was separated from the other region of kidney using a sharp blade 154 
and the cortical tissue was minced using two sharp blades. The cortical tissue was then sonicated in a 155 
lysis buffer followed by centrifugation at 20817 g for 15 min at 4ºC. The supernatants were collected for 156 
Western blot. 157 
Immunofluorescence staining Anti-desmin goat polyclonal antibody (Santa Cruz, Catalog #: sc-7559) 158 
and Alexa Fluor 488 donkey anti-goat IgG (Catalog #: A11055, Life Technologies, Eugene, OR) were 159 
used to label mouse glomerular MCs. Anti-synaptopodin goat polyclonal antibody (Santa Cruz, catalog 160 
#: sc-21537) and Alexa Fluor 488 donkey anti-goat IgG (Catalog #: A11055, Life Technologies, Eugene, 161 
OR) was used to label podocytes. Anti-Col IV rabbit polyclonal antibody (Abcam, Catalog#: ab6586) 162 
and Alexa Fluor 488 goat anti-rabbit IgG (Catalog #: A11008, Life Technologies, Eugene, OR) were 163 
used to stain Col IV. Anti-Smad1 mouse monoclonal antibody (Santa Cruz, Catalog #: sc-81378) and 164 
Alexa Fluor 488 goat anti-mouse IgG (Catalog #: A21202, Life Technologies, Eugene, OR) was used to 165 
stain Smad1. All primary antibodies were diluted at 1:100 and all secondary Alexa Fluor antibodies 166 
were diluted at 1:200. Sections were visualized using an Olympus microscope (BX41) equipped for 167 
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epifluorescence and an Olympus DP70 digital camera with DP manager software (version 2.2.1). 168 
Sections were coded and viewed by an observer masked to their origins. Images were uniformly 169 
adjusted for brightness and contrast and converted to 8-bit format for measuring fluorescence intensity 170 
using Image J (version 1.50b, NIH). 171 
Statistical Analysis Data were reported as means ± SE. The one-way ANOVA plus Student-Newman-172 
Keuls post-hoc analysis and Student unpaired t-test were used to analyze the differences among multiple 173 
groups and between two groups, respectively. P<0.05 was considered statistically significant. Statistical 174 
analysis was performed using SigmaStat (Jandel Scientific, San Rafael, CA). 175 
  176 
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RESULTS 177 
SOCE decreased abundance of Smad1 protein in human MCs. 178 
To determine if SOCE regulated Smad1 signaling, we carried out Western blot and examined effects 179 
of inhibition and activation of SOCE on content of Smad1 protein. As shown in Fig. 1 A&B, treating 180 
MCs with an SOCE inhibitor, 2-APB (50 µM) significantly increased abundance of Smad1 protein. 181 
However, this response was not observed in the cells treated with methanol, the vehicle control of 2-182 
APB. 183 
It was reported that the products of hyperglycemia stimulated synthesis of Smad1 protein in MCs (3). 184 
We next examined if SOCE affected high glucose-stimulated Smad1 protein production. Incubation of 185 
MCs with high glucose (25 mM) for 3 days significantly increased amount of Smad1 protein (Fig. 1 186 
C&D). However, activation of SOCE by TG (1 µM) in the cells exposed to high glucose for the same 187 
time period significantly blunted the Smad1 response (Fig. 1 E&F). These results suggest that SOCE 188 
reduced Smad1 protein abundance in human MCs under unstimulated and stimulated (high glucose) 189 
conditions. 190 
SOCE inhibited phosphorylation of Smad1 in human MCs. 191 
In addition to reducing the protein amount, suppressing protein activity might be another mechanism 192 
for SOCE regulating Smad1 pathway. Like other classical Smad signaling, Smad1 pathway is activated 193 
by phosphorylation. It has been reported that Ang II at 1 µM activated Smad1 signaling by 194 
phosphorylation of Smad1 in MCs in a time dependent manner, peaking at 15 min (30). We thereby 195 
examined if activation of SOCE could inhibit Ang II-induced Smad1 phosphorylation. In agreement 196 
with the published study (30), treating human MCs with Ang II at 1 µM for 15 min significantly 197 
increased phosphorylated Smad1 without changes in the total amount of Smad1. However, in the 198 
presence of TG (1 µM), but not DMSO (1:1000) the Ang II-induced Smad1 phosphorylation was not 199 
observed (Fig. 2 A&B). 200 
12 
 
We next examined if high glucose could also induce phosphorylation of Smad1 and SOCE could also 201 
inhibit the phosphorylation. As shown in Fig. 2 C&D, high glucose treatment increased the level of 202 
phospho-Smad1. However, the ratio of phospho-Smad1 to the total amount of Smad1 was not 203 
significantly increased because high glucose also increased the total amount of Smad1 as shown in Fig. 204 
1 E&F. Interestingly, activation of SOCE with TG resulted in a greater decrease in phospho-Smad1 205 
level than the decrease in the total abundance of Smad1, leading to a significant decrease in ratio of 206 
phospho-Smad1 to total Smad1 (Fig. 2 E&F). 207 
It is generally acknowledged that Smad1 transduces bone morphogenetic protein signals (4; 43). 208 
However, recent studies demonstrated that TGF-β1 also activated Smad1 pathway in a variety of cells (5; 209 
32). To further determine the inhibitory effect of SOCE on Smad1 activation, we examined if activation 210 
of SOCE could decrease TGF-β1-induced phosphorylation of Smad1. As shown in Fig. 3 A&B, 211 
treatment of human MCs with 5 ng/ml TGF-β1 significantly increased phospho-Smad1 as early as 30 212 
min after treatment and this response sustained at least for 240 min. However, the total amount of 213 
Smad1 had no change during the period of treatment. This TGF-β1-stimulated Smad1 activation was 214 
dramatically reduced by TG treatment (Fig. 3 C&D). Furthermore, the inhibitory effect of TG was 215 
prevented by 2-APB and La3+ (Fig. 3 E&F), suggesting that the inhibition of TG on the TGF-β1/Smad1 216 
pathway was attributed to activation of SOCE, but not by a possible ER stress. 217 
Taken together, the data presented in Figs. 2 and 3 suggest that SOCE inhibited activation of Smad1 218 
signaling in human MCs. 219 
Smad1 increased abundance of Col IV protein in human MCs. 220 
Smad1 has been shown to be a key molecule for direct transcriptional regulation of Col IV in mouse 221 
MCs (3). To determine if Smad1 regulates Col IV protein content in human MCs, we manipulated 222 
Smad1 expression level and evaluated how it affected Col IV protein abundance in cultured human MCs. 223 
We found that knockdown of Smad1 using RNAi approach significantly reduced abundance of Col IV 224 
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protein (Fig. 4 A&B). Efficiency of the Smad1 siRNA was indicated by a marked decrease in Smad1 225 
protein content in the cells treated with the siRNA, but not by its scramble control (Fig. 4C). 226 
Furthermore, over expression of Smad1 increased Col IV protein content (Fig. 4D). These data, 227 
combined with the previous study that Smad1 directly activated transcription of Col IV (3), suggest that 228 
production of Col IV is a result of activation of Smad1 pathway in human MCs. 229 
SOCE decreased abundance of Col IV protein produced by human MCs. 230 
The experiments presented above (Fig. 4) showed that activation of Smad1 pathway stimulated Col 231 
IV protein production. If SOCE suppressed Smad1 signaling, then this Ca2+ signal should inhibit 232 
production of Col IV. 233 
High glucose is known to activate Smad1 pathway and stimulate production of Col IV protein by 234 
MCs (3; 6; 42). To determine effect of SOCE on Col IV protein production in MCs, we examined if 235 
activation of SOCE could inhibit high glucose-induced Col IV response. As shown in Fig. 5 A&B, high 236 
glucose (25 mM) treatment for 3 days significantly increased content of Col IV protein in human MCs. 237 
This response was abolished by TG (1 µM), but not by its vehicle (DMSO). In agreement with these 238 
results, inhibition of SOCE with 50 μM 2-APB or 2 µM lanthanum (La3+) both of which are inhibitors 239 
of store-operated Ca2+ channel (27; 35), significantly increased Col IV protein abundance. However, this 240 
response was not observed in the cells treated with methanol, the vehicle control for 2-APB (Fig. 5 241 
C&D). These data are consistent with our previous study (46) and suggest that SOCE inhibited Col IV 242 
protein production by MCs. 243 
In vivo suppression of SOCE in MCs increased expression of glomerular Smad1 protein in mice. 244 
We next carried out animal study to verify our in vitro findings. Orai1 is the pore-forming unit of 245 
store-operated Ca2+ channel (11; 44). Our recent study demonstrated that knocking down Orai1 using 246 
siRNA nearly eliminated SOCE in cultured human MCs (8). We thereby speculated that we could 247 
inhibit SOCE in MCs in vivo by delivery of siRNA against Orai1 to intact animals. Using the targeted in 248 
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vivo NP/siRNA delivery system (46; 48), we treated mice with Cy3-tagged siRNA against mouse Orai1 249 
(NP-Cy3-siOrai1) which was carried by NPs through tail vein injection using the protocol described in 250 
our previous studies (46; 48). Consistent with our previous reports (46; 48), the NP/siRNA complexes 251 
were restricted to glomeruli and were not detectable in the surrounding renal tubules or interstitium (Fig. 252 
6A). By labeling MCs with desmin and podocytes with synaptopodin, we further identified that the 253 
siRNAs were predominantly localized in MCs, but not in podocytes (Fig. 6B). Western blot of renal 254 
cortical extracts showed that Orai1 protein abundance was significantly reduced in the siRNA-treated 255 
mice compared to NP alone-treated mice (Fig. 6 C&D). These data suggest that our in vivo NP delivery 256 
system could deliver functional siRNA specifically to MCs in mice. 257 
We then performed immunofluorescence staining to examine the effect of in vivo knockdown of 258 
Orai1 specifically in MCs on Smad1 protein expression in mice. Consistent with a published study (18), 259 
the expression of Smad1 was only detected in tubules, but not detectable in glomeruli in normal (control) 260 
adult mouse (Fig. 7A). However, the glomeruli with Orai1 knocked down in the mice receiving NP-261 
Cy3-siOrai1 showed strong staining of Smad1 (Fig. 7 A&B). Consistently, abundance of Smad1 protein 262 
in renal cortex was also significantly increased in the siRNA-treated mice (Fig. 7 C&D). These in vivo 263 
data are consistent with our in vitro data (Fig. 1) and further suggest that SOCE decreased Smad1 264 
protein abundance in MCs. 265 
In vivo suppression of SOCE in MCs increased glomerular Col IV protein in mice. 266 
We also conducted immunohistochemical and biochemical examinations to assess changes in 267 
glomerular Col IV protein content in the mice with and without knockdown of Orai1. In the mice treated 268 
with NP alone, Col IV staining in glomerulus was mild. However, in the mice receiving NP-Cy3-siOrai1 269 
the immunofluorescence of Col IV in the glomeruli positively transfected with Orai1 siRNA was 270 
significantly greater (Fig. 8 A&B). Consistently, abundance of Col IV protein in renal cortex was also 271 
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significantly increased in the siRNA-treated mice (Fig. 8 C&D). These data provided in vivo evidence 272 
that inhibition of SOCE in MCs increased glomerular Col IV protein abundance. 273 
  274 
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DISCUSSION 275 
Glomerular MCs sit between glomerular capillary loops and maintain the structural architecture of 276 
the capillary networks. These cells play important roles in mesangial matrix homeostasis, regulation of 277 
glomerular filtration rate and phagocytosis of apoptotic cells in glomerulus (1; 39). MC dysfunction is 278 
closely associated with several glomerular diseases, such as diabetic nephropathy (20; 40). Like many 279 
other cell types, MC function is largely regulated by intracellular Ca2+ signals and the MC Ca2+ 280 
homeostasis is, at a large extent, attributed to Ca2+ channels in the plasma membrane (25). Over past 281 
decades, we and others have demonstrated that SOCE mediates MC Ca2+ responses to a variety of 282 
circulating and locally produced hormones (7; 26; 33). However, the functional roles of SOCE signaling 283 
in MC physiology and pathology have remained unclear until recently we demonstrated that this Ca2+ 284 
entry decreased production of matrix proteins (fibronectin and Col IV) (46). The present study extended 285 
our previous findings on the beneficial effects of SOCE. More importantly, this study provided in vitro 286 
and in vivo evidence that Smad1 is involved in the anti-fibrotic effect of SOCE in MCs.  287 
Accumulation of extracellular matrix proteins, including those generated by MCs, is a major 288 
pathological change in glomerulus in early stage of diabetic kidney disease (9). Col IV is a major 289 
component of increased glomerular extracellular matrix in diabetic nephropathy. During the process of 290 
glomerular injuries, MCs can overproduce Col IV (13). Smad1 has been shown to be a key molecule for 291 
direct transcriptional regulation of Col IV in MCs (3). In the present study, we also showed that 292 
downregulation of Smad1 decreased and upregulation of Smad1 increased Col IV protein abundance in 293 
MCs. Thus, our study is consistent with the previous study and suggest existence of an Smad1-Col IV 294 
pathway in glomerular MCs. 295 
The most important finding from the present study is that SOCE is a negative regulator of Smad1 296 
signaling. Like other receptor-regulated Smads, Smad1 signaling is initiated with phosphorylation by 297 
type I receptors of TGF-β superfamily. The activity of Smad1 pathway can be altered by a change of 298 
17 
 
either the total protein amount or the phosphorylation state of Smad1. Our data from the present study 299 
showed that SOCE inhibited Smad1 signaling through both mechanisms. Inhibition of SOCE both in 300 
vitro and in vivo significantly increased the total amount of Smad1 in cultured MCs and in glomeruli of 301 
mice. Activation of SOCE abolished high glucose-induced increase in abundance of Smad1. In addition, 302 
activation of SOCE substantially attenuated phosphorylation of Smad1 by Ang II, high glucose, and 303 
TGF-β1, all of which are known pathological stimuli in the process of diabetic nephropathy (22; 36; 47). 304 
Recent studies revealed that both glomerular expression of Smad1 and urinary excretion of Smad1 305 
were increased significantly in diabetic rats along with mesangial expansion (30). Further study showed 306 
that the increase of urinary Smad1 in the early stage of diabetes was correlated with later development 307 
of glomerulosclerosis in two rodent models of diabetic nephropathy (29). Thus, urinary Smad1 could be 308 
used as a biomarker for diabetic nephropathy (21; 29) and inhibition of Smad1 pathway should be 309 
beneficial to kidney under conditions of diabetes. Our finding that SOCE is an inhibitory mechanism for 310 
deleterious Smad1 signaling in MCs suggest that pharmacological and biological increase of SOCE in 311 
MCs could protect kidney from diabetic injury and thereby could be a therapeutic option for diabetic 312 
kidney disease. 313 
It has been firmly established that TGF-β1 plays the most crucial role in glomerular matrix 314 
accumulation in diabetic nephropathy (47). Smad 2/3 is the classical downstream pathway activated by 315 
TGF-β1 (2; 24). However, TGF-β1 also activates Smad1 pathway in a variety of cells, including MCs (5; 316 
32). The role of TGF-β1/Smad1 pathway in regulation of extracellular protein expression is cell type- 317 
and cell context-dependent. In several cell types, such as endothelial cells, Smad1 signaling counteracts 318 
TGF-β1/Smad2/3-induced matrix protein expression (16). However, in hepatic stellate cells and 319 
scleroderma fibroblasts, TGF-β1/Smad1 pathway promotes fibrotic phenotype (31; 34; 45). Particularly, 320 
the present study and a recent study from other group (5) demonstrated that the TGF-β1/Smad1 pathway 321 
promoted matrix protein expression in MCs. Because indiscriminate complete blockade of TGF-β 322 
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function does not protect kidney from diabetic injury (41), therapeutic targeting of TGF-β1 requires 323 
more optimal strategies such as those selectively directed at specific signaling pathway. Smad1, as a 324 
downstream signaling molecule of TGF-β1 and a fibrotic factor in MCs, could be a candidate of this 325 
kind of therapeutic targets. The present study suggest that SOCE is an endogenous suppressor of Smad1 326 
signaling and thus manipulation of SOCE in MCs could be a strategy intervening the detrimental Smad1 327 
pathway to ameliorate renal injury in diabetes.  328 
This study has a couple of limitations that must be acknowledged. Firstly, the study is mainly 329 
descriptive, limiting the determination of mechanisms by which SOCE suppresses Smad1 pathway. 330 
Because our data showed that activation of SOCE decreased both abundance and activity 331 
(phosphorylation) of Smad1 protein, multiple mechanisms might be involved in the SOCE inhibitory 332 
responses. Regarding inhibition on Smad1 phosphorylation by SOCE, several possibilities exist.  At the 333 
level of TGF-β receptors, SOCE may inhibit the type II or type I receptor kinase which in turn, 334 
suppresses the subsequent phosphorylation of Smad1. Another   possibility is that SOCE either activates 335 
a Ca2+ dependent phosphatase or inhibits a protein kinase which uses Smad1 as its substrate. 336 
Alternatively, SOCE could facilitate the interaction between an inhibitory Smad and the TGF-β 337 
receptors, leading to inactivation of the downstream Smad1 signaling. Study has shown that the 338 
inhibitory Smad is present and functional in MCs (17). Secondly, it is not clear whether inhibition of 339 
Smad1 pathway by SOCE is a general mechanism or a MC specific mechanism. In terms of regulation 340 
of protein synthesis, the function of SOCE is cell type specific and cell context dependent (19; 37). This 341 
is also true in kidney cells. For instance, we and others demonstrated that SOCE inhibited fibronectin 342 
and Col IV protein production in glomerular MCs (28; 46), but it increased abundance of the matrix 343 
proteins produced by the proximal tubular epithelial cells (28). Thus, the findings in MCs from this 344 
study may not be able to extend to other cell types. Despite these limitations, the current studies in vitro 345 
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and in vivo suggest that Smad1 pathway and the matrix protein (Col IV) produced by activation of this 346 
pathway are under control of SOCE in MCs. 347 
In summary, we defined a negative regulation of Smad1 signaling pathway and Col IV protein 348 
expression by SOCE in MCs. The inhibition on Smad1 signaling was through both decreasing protein 349 
content of Smad1 and suppressing phosphorylation of Smad1. Because Smad1 signaling is associated 350 
with the development of diabetic kidney disease and over production of Col IV is one of major 351 
pathological changes in glomeruli of diabetic kidney, our findings suggest that SOCE in MCs may be an 352 
alternative therapeutic option for treating patients with diabetic nephropathy. 353 
 354 
 355 
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FIGURE LEGENDS 504 
Fig. 1. Western blot, showing effect of SOCE on Smad1 protein content in human MCs. 505 
A and B: Inhibition of SOCE increased Smad1 protein abundance. A: Representative western blots. 506 
Cultured human MCs were without treatment (UT) or treated with methanol (Meth) (1:1000, vehicle 507 
control for 2-APB) and 2-APB (50 µM) for 2 days. L: protein ladder. Tubulin (TB): loading control. B: 508 
Summary data from the experiments presented in A. * denotes P<0.05, 2-APB vs. both UT and Meth 509 
groups. C and D: High glucose treatment increased Smad1 protein abundance.  C: Representative 510 
western blots. L: protein ladder. Tubulin (TB): loading control. Confluent human MCs were cultured in 511 
serum free medium containing normal glucose (NG, 5.6 mM D-glucose + 20 mM mannitol) or high 512 
glucose (HG, 25 mM D-glucose) for 1 day (1D) and 3 days (3D). D: Summary data from the 513 
experiments presented in C. * denotes P<0.05, compared to NG group at the same time point. “n” 514 
indicates the number of independent experiments. E and F: Activation of SOCE inhibited high glucose-515 
stimulated Smad1 production. E: Representative western blots. L: protein ladder. Tubulin (TB): loading 516 
control. Confluent human MCs were cultured in serum free medium containing normal glucose (NG, 5.6 517 
mM D-glucose + 20 mM mannitol) or high glucose (HG, 25 mM D-glucose) for 3 days. In two groups 518 
with high glucose treatment, DMSO (1:1000, vehicle control) and TG (1 μM) were applied on day 2. F: 519 
Summary data from the experiments presented in E. * denotes P<0.05, compared to NG group. † 520 
denotes P<0.05, compared to both HG and HG+DMSO groups. “n” indicates the number of independent 521 
experiments. 522 
Fig. 2. Western blot, showing inhibition of phosphorylation of Smad1 by SOCE in human MCs 523 
A and B: Activation of SOCE inhibited Ang II-induced phosphorylation of Smad1. A: 524 
Representative Western blot, showing changes in abundance of phosphorylated Smad1 (p-Smad1) and 525 
total Smad1 (T-Smad1) proteins in different treatment groups. Human MCs were without treatment (UT) 526 
or treated with Ang II (1 µM) for 15 min in the presence of DMSO (1:1000, vehicle control for TG) or 527 
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TG (1 μM). L: a protein ladder. B: summary data from the experiments presented in A, showing the 528 
ratio of p-Smad1 to T-Smad1 in different groups. * denotes p<0.05, vs UN; † denotes p<0.05; vs. both 529 
Ang II and Ang II + DMSO. “n” indicates the number of independent experiments. C and D: Activation 530 
of SOCE inhibited high glucose-induced phosphorylation of Smad1. C: Representative western blots, 531 
showing changes in abundance of phosphorylated Smad1 (p-Smad1) and total Smad1 (T-Smad1) 532 
proteins in different treatment groups. Serum-deprived human MCs were cultured in normal glucose 533 
(NG, 5.6 mM D-glucose + 20 mM mannitol) or high glucose (HG, 25 mM D-glucose) for 3 days. In two 534 
groups with high glucose treatment, DMSO (1:1000, vehicle control) and TG (1 μM) were applied on 535 
day 2. L: protein ladder. D: Summary data from the experiments presented in C, showing the ratio of p-536 
Smad1 to T-Smad1 in different groups. * denotes P<0.05, compared to both HG and HG+DMSO groups. 537 
“n” indicates the number of independent experiments. 538 
Fig. 3. SOCE inhibited TGF-β1-induced phosphorylation of Smad1 in human MCs. 539 
A and B: TGF-β1 phosphorylated Smad1. A: Representative Western blot, showing changes in 540 
abundance of phosphorylated Smad1 (p-Smad1) and total Smad1 (T-Smad1) in MCs treated with 541 
recombinant human TGF-β1 (5 ng/ml) for 0 to 240 min. B: summary data from the experiments 542 
presented in A, showing the ratio of p-Smad1 to T-Smad1 at different treatment time periods. * denotes 543 
p<0.05, vs group of 0 min. “n” indicates the number of independent experiments. C and D: Activation 544 
of SOCE inhibited TGF-β1-induced phosphorylation of Smad1. C: Representative Western blots, 545 
showing changes in abundance of phosphorylated Smad1 (p-Smad1) and total Smad1 (T-Smad1) in 546 
different groups. Serum-deprived human MCs were without treatment (UT) or treated with TGF-β1 (5 547 
ng/ml for 30 min) in the presence of DMSO (1:1000) or TG (1 µM). D: Summary data from the 548 
experiments presented in C, showing the ratio of p-Smad1 to T-Smad1 in different groups. * denotes 549 
P<0.05, compared to UT; † denotes P<0.05, compared to both TGF-β1 and TGF-β1 + DMSO.  “n” 550 
indicates the number of independent experiments. E and F: Inhibition of TG on TGF-β1-induced 551 
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phosphorylation of Smad1 was due to activation of SOCE. E: Representative Western blots, showing 552 
the abundance of phosphorylated Smad1 (p-Smad1) and total Smad1 (T-Smad1) in serum-deprived 553 
human MCs treated with TGF-β1 (5 ng/ml for 30 min) in the absence or presence of TG (1 µM) with 554 
and without 2-APB (50 µM) or La3+ (2 µM). F: Summary data from the experiments presented in E, 555 
showing the ratio of p-Smad1 to T-Smad1 in different groups. * denotes P<0.05, compared to TGF-β1; † 556 
denotes P<0.05, compared to TGF-β1 + TG.  “n” indicates the number of independent experiments. 557 
Fig. 4. Smad1 increased Col IV protein abundance in human MCs 558 
A: Representative Western blot, showing Col IV protein content in human MCs without transfection 559 
(UTran) and the cells transfected with scramble siRNA (Scram) or siRNA against human Smad1 560 
(siSmad1). α-tubulin (TB) was used as a loading control. L: protein ladder. B: Summary data from the 561 
experiments presented in A. Col IV abundance in each group was normalized to TB and the values in 562 
each group were further normalized to that of Utran group. * denotes P<0.05, compared to both Utran 563 
and Scram groups. “n” indicates the number of independent experiments. C: Representative Western 564 
blot from 3 independent experiments, showing Smad1 protein content in human MCs without 565 
transfection (UTran) and the cells transfected with Scramble siRNA (Scram) or siRNA against Smad1 566 
(siSmad1). β-actin was used as a loading control. L: protein ladder. D: Representative western blot from 567 
3 independent experiments, showing abundance of Smad1 and Col IV proteins in human MCs without 568 
transfection (UTran) and the cells transfected with an empty vector (pSHAG) or Flag-tagged Smad1 569 
expresion plasmid (Flag-Smad1). α-tubulin (TB) was used as a loading control. L: protein ladder. 570 
Fig. 5. SOCE decreased abundance of Col IV protein produced by human MCs. 571 
A and B: Effect of activation of SOCE on high glucose-stimulated Col IV protein production. A: 572 
Representative Western blots. L: protein ladder. Tubulin (TB): loading control. B: Summary data from 573 
the experiments presented in A. Human MCs were cultured in medium containing normal glucose (NG, 574 
5.6 mM D-glucose + 20 mM mannitol) or high glucose (HG, 25 mM D-glucose) with or without DMSO 575 
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(1:1000, vehicle control) and TG (1 μM). MCs were with and without various treatments for 2 days in 576 
0.5% FBS medium. In B, * denotes P<0.05, compared to NG group and † denotes P<0.05, compared to 577 
both HG and HG+DMSO groups. “n” indicates the number of independent experiments. C and D: 578 
Effect of inhibition of SOCE on Col IV protein production in human MCs. C: Representative Western 579 
blots. L: protein ladder. Tubulin (TB): loading control. D: Summary data from the experiments 580 
presented in C. UT: untreated cells; Meth: methanol, vehicle control for 2-APB. Serum starved cells (in 581 
0.5% FBS) were with or without treatments with methanol (1:1000), or 2-APB (50 μM) or La3+ (5 µM) 582 
for 2 days before harvested. In D, * denotes P<0.05, compared to both UT and Meth groups. “n” 583 
indicates the number of independent experiments. 584 
Fig. 6. Distribution of NP-Cy3-siOrai1 in mouse kidney 585 
A: Representative images from 4 mice, showing localization of NP-Cy3-siOrai1 (red) in glomeruli 586 
(indicated by arrows). Original magnification: 200X. B: Localization of NP-Cy3-siOrai1 in MCs (upper 587 
panels), but not in podocytes (bottom panels), representative from 4 mice. MCs were stained with 588 
desmin (green) and podocytes were stained with synaptopodin (green). NP-Cy3-siOrai1 was shown as 589 
red signals. Original magnification: 200X. C: Representative Western blot of renal cortical extracts, 590 
showing Orai1 protein abundance in the mouse treated with NP alone (NP-Con) and NP containing 591 
siRNA against Orai1 (NP-siOrai1).  L: protein ladder; Tubulin (TB): loading control. D: Summary data. 592 
* denotes P<0.05, compared to NP-Con; “n” indicates the number of mice each group. 593 
Fig. 7. In vivo knockdown of Orai1 in MCs increased glomerular Smad1 protein in mice. 594 
A: Representative images of Immunofluorescence staining, showing glomerular Smad1 in the mouse 595 
treated with NP alone (NP-Con) and NP-Cy3-siOrai1 (knockdown of Orai1). Smad1 is shown as green 596 
signals. In the panels of NP-Con, a bright field image was captured to show glomeruli. In the panels of 597 
NP-Cy3-siOrai1, the distribution of NP-Cy3-siOrai1 is indicated by Cy3 signals (red). Arrows indicate 598 
glomeruli. Original magnification: 200X. B: Integrated density (ID) of Smad1 fluorescence averaged 599 
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from 4 NP-Con mice and 4 NP-Cy3-siOrai1-treated mice. ** denotes P<0.01, compared to NP-Con. The 600 
numbers in parentheses under each bar represent the number of glomeruli counted from 5 sections per 601 
kidney. C and D: Western blot, showing Smad1 protein abundance in the cortex of kidney from the 602 
mouse treated with NP alone (NP-Con) and NP-Cy3-siOrai1 (NP-siOrai). C: Representative blot. L: 603 
protein ladder; TB: α-tubulin, a loading control. D: summary data. * denotes P<0.05, compared to NP-604 
Con. “n” indicates the number of mice each group. 605 
Fig. 8. In vivo knockdown of Orai1 in MCs increased glomerular Col IV protein in mice.  606 
A: Representative images of Immunofluorescence staining, showing glomerular Col IV in the mouse 607 
treated with NP alone (NP-Con) and NP-Cys-siOrai1 (knockdown of Orai1). Col IV is shown as green 608 
signals. In the panels of NP-Con, a bright field image was captured to show glomeruli. In the panels of 609 
NP-Cy3-siOrai1, the distribution of NP-Cy3-siOrai1 is indicated by Cy3 signals (red). Arrows indicate 610 
glomeruli. Original magnification: 200X. B: Integrated density (ID) of Smad1 fluorescence averaged 611 
from 4 NP-Con mice and 4 NP-Cy3-siOrai1-treated mice. ** denotes P<0.01, compared to NP-Con. The 612 
numbers in parentheses under each bar represent the number of glomeruli counted from 5 sections per 613 
kidney. C and D: Western blot, showing Smad1 protein abundance in the cortex of kidney from the 614 
mouse treated with NP alone (NP-Con) and NP containing siRNA against Orai1 (NP-siOrai1). C: 615 
Representative blot. L: protein ladder; TB: α-tubulin, a loading control. D: summary data. * denotes 616 
P<0.05, compared to NP-Con. “n” indicates the number of mice each group. 617 
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